The 14th Biosimilars Congregation 2019 is a congress that covers topics such as:
Biosimilar development in emerging markets
Current market trends and future challenges for Biosimilar success
Commercial challenges and opportunities - strategies to develop Biosimilars
Redesigning the Biosimilar business model: What is the optimum business model for Biosimilars?
How do payers see Biosimilars and where is the market going?
Leading Biosimilars companies share their views and strategies on successful market penetration and learn to implement best practices through recent successful strategies and business models – real time case studies
Advances in Biosimilar clinical development and resulting regulatory challenges and opportunities
Developing successful business models in Biosimilar product development
Biosimilars development and impact on clinical practice
Non-Clinical Studies in Biosimilars development
Research-based industry Biosimilar strategies
Capturing the mAb Biosimilar opportunity
Considerations for the analytical similarity assessments when designing a Biosimilar development program
Gain in-depth knowledge on role of technology transfer - How does this effect market access?
Understanding the current regulatory approval standards for Biosimilars in Europe, US and ROI including for monoclonal antibodies
Determining the right investments & potential returns from Biosimilars
The 14th Biosimilars Congregation 2019 brings together senior attendees with responsibilities in:
Follow on Biologics/Follow on Proteins
Pricing and Reimbursement
Chief Scientific Officer
Process Control and Analytical Technologies
Quality Affairs/ Quality Control
Drug Safety & Risk Management
New Product Development
Research & Development
The 14th Biosimilars Congregation 2019 will be held in Mumbai, India on 12 December 2019.